Stocks to Watch: Lincare, Amylin, Brightpoint

Among the companies with shares expected to actively trade in Monday’s session are Lincare Holdings Inc. (LNCR), Amylin Pharmaceuticals Inc. (AMLN) and Brightpoint Inc. (CELL). 

Linde AG (LIN.XE), a German supplier of industrial gas, said Sunday it plans to acquire Lincare Holdings Inc. (LNCR), a U.S. provider of respiratory therapy, oxygen and other services to patients at home, for about $4.6 billion. Lincare shares rose 21% to $41.14 premarket. 

Bristol-Myers Squibb Co.’s (BMY) agreement to acquire diabetes-drug maker Amylin Pharmaceuticals Inc. (AMLN) for $5.3 billion gives Bristol more heft in a fast-growing market, but the New York-based pharmaceutical company still faces larger rivals with dominant products. Amylin shares climbed 9% to $30.74. 

Supply-chain-services provider Ingram Micro Inc. (IM) agreed to acquire wireless-equipment provider Brightpoint Inc. (CELL) for roughly $622 million as it looks to expand in the mobility market. Ingram will pay $9 a share, a 66% premium to Brightpoint’s Friday close. Brightpoint shares surged 63% to $8.81 premarket. 

Ampio Pharmaceuticals Inc. (AMPE) entered an agreement with India-based Syngene to manufacture a combination product to treat both premature ejaculation and erectile dysfunction in a Phase 3 trial. The combination product, known as Zertane-ED, will be used in trials in South Korea with the biopharmaceutical company’s partner Daewoong Co. (003090.SE), which will finance and conduct the trials. Shares of Ampio jumped 14% to $5.78 in premarket trading. 

Anworth Mortgage Asset Corp. (ANH) cut its quarterly dividend 14%. The real-estate investment trust said it reinvested scheduled repayments of principal and prepayments of principal from its primarily adjustable-rate mortgage asset portfolio into mortgage assets with interest rates that were lower than what it earned on the principal amount. The company also said interest income in the latest period was hurt by projected premium amortization expense, which is expected to increase from the prior quarter. Shares dropped 5.1% to $6.69 premarket. 

Amarin Corp. (AMRN) confirmed the U.S. Patent and Trademark Office published notification of a Notice of Allowance supporting its use of a fish-oil heart pill in patients with high triglycerides. The notice, which is typically issued after U.S. regulators determine a patent can be granted from an application, was posted for Amarin’s patent application serial number 12/769,885 for a “highly stable EPA in a capsule.” Eicosapentaenoic acid, or EPA, is one of the most important omega-3 fatty acids contained in fish oil. Amarin is pursuing more than 25 pending U.S. patent applications to guard the commercial potential for AMR101 to 2030 and further. Shares rose 2.8% to $14.86 premarket. 

Corcept Therapeutics Inc. (CORT) plans to sell about 11 million common shares as the drug developer aims to raise funds for research and development and other purposes. The company focuses on the development of drugs for severe psychiatric and metabolic disorders, such as the rare endocrine disorder Cushing’s syndrome and psychotic depression. Corcept’s first U.S. Food and Drug Administration approved medication, Korlym for some patients with Cushing’s syndrome, was introduced earlier this year. Shares were 5.1% lower at $4.26 premarket. 

FactSet Research Systems Inc. (FDS) acquired news management company StreetAccount LLC, adding more content to its market analysis databases. Financial terms weren’t disclosed. The StreetAccount service includes real-time company updates, sector filtering and market summaries, written by financial professionals. FactSet has been StreetAccount’s sole distributor since earlier this year. 

FedEx Corp. (FDX) continued to reconfigure its aircraft fleet Friday, disclosing it is buying additional fuel-efficient jets for its domestic routes to replace older models while trimming the number of new Boeing Co. (BA) 777 long-range freighters on order to fly between the U.S. and Asia. 

Micron Technology Inc. (MU) agreed to acquire troubled Japanese rival Elpida Memory Inc. through a definitive sponsor agreement that will see the chipmaker spend about $2.5 billion to buy the company’s equity and pay some of its creditors. Micron became Elpida’s financial sponsor in May after the maker of DRAM filed for bankruptcy protection. Micron will acquire the company’s equity for $750 million and pay a total of $1.75 billion in future annual installment payments. All pre-petition debt obligations of Elpida will be discharged under the corporate reorganization proceedings. Micron shares were trading 3.7% higher at $6.54 premarket.

No comments:

Post a Comment

Superhit News

News Archive